Bio-Rad Laboratories Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	2,583	2,567	2,671	2,802	2,923
Revenue Growth (YoY)	0.65%	-3.92%	-4.67%	-4.12%	14.81%
Cost of Revenue	1,240	1,173	1,240	1,235	1,259
Gross Profit	1,344	1,394	1,431	1,567	1,663
Selling, General & Admin	819.8	810.2	824.2	827.8	851.02
Research & Development	257.6	294.3	240.9	256.9	247.34
Operating Expenses	1,077	1,105	1,065	1,085	1,098
Operating Income	266.2	289.2	365.7	482.6	564.74
Interest Expense	-49	-48.9	-49.4	-38.1	-1.55
Interest & Investment Income	95.5	82	100.9	58.1	18.9
Currency Exchange Gain (Loss)	6.6	3.9	7.3	0.2	-2.75
Other Non Operating Income (Expenses)	-0.3	3.2	4.9	-5.2	0.68
EBT Excluding Unusual Items	319	329.4	429.4	497.6	580.01
Merger & Restructuring Charges	-46.1	-21.8	-27.9	-	-64.4
Gain (Loss) on Sale of Investments	895.4	-2,650	-1,252	-5,203	4,933
Gain (Loss) on Sale of Assets	-	-	-	1.4	-
Asset Writedown	-172.8	-	-	-	-
Pretax Income	995.5	-2,343	-850.1	-4,704	5,449
Income Tax Expense	235.6	-498.3	-212.8	-1,077	1,195
Net Income	759.9	-1,844	-637.3	-3,628	4,254
Net Income to Common	759.9	-1,844	-637.3	-3,628	4,254
Net Income Growth	-	-	-	-	11.54%
Shares Outstanding (Basic)	27	28	29	30	30
Shares Outstanding (Diluted)	27	28	29	30	30
Shares Change (YoY)	-3.31%	-3.41%	-1.93%	-1.40%	0.16%
EPS (Basic)	27.85	-65.36	-21.82	-121.79	142.61
EPS (Diluted)	27.85	-65.36	-21.82	-121.79	140.83
EPS Growth	-	-	-	-	11.35%
Free Cash Flow	374.6	289.6	218.2	81.6	535.75
Free Cash Flow Per Share	13.73	10.26	7.47	2.74	17.74
Gross Margin	52.01%	54.30%	53.56%	55.93%	56.91%
Operating Margin	10.30%	11.27%	13.69%	17.22%	19.32%
Profit Margin	29.42%	-71.86%	-23.86%	-129.45%	145.57%
Free Cash Flow Margin	14.50%	11.28%	8.17%	2.91%	18.33%
EBITDA	431.6	440.8	511.6	619.9	702.34
EBITDA Margin	16.71%	17.18%	19.15%	22.12%	24.03%
D&A For EBITDA	165.4	151.6	145.9	137.3	137.6
EBIT	266.2	289.2	365.7	482.6	564.74
EBIT Margin	10.30%	11.27%	13.69%	17.22%	19.32%
Effective Tax Rate	23.67%	-	-	-	21.93%

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q